VJDementia Podcast podcast

Expert perspectives on lecanemab

0:00
22:37
Rewind 15 seconds
Fast Forward 15 seconds

On January 6, 2023, the US FDA approved lecanemab for the treatment of Alzheimer’s disease (AD), making history as the first ever treatment to significantly slow cognitive decline. Despite the excitement surrounding this breakthrough approval, concerns remain regarding the extent of lecanemab's clinical benefit and the risks involved with its use. In this episode, experts delve review the evidence, reflecting on the performance of lecanemab and future directions for anti-amyloid therapies.

More episodes from "VJDementia Podcast"